MIRMAZY
DEAD

Serial Number

90860817

Owner

Celgene Corporation

Attorney

Xiomara Triana

Filing Date

Aug 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MIRMAZY Trademark

Serial Number: 90860817

MIRMAZY is a trademark filed by Celgene Corporation on August 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

August 2, 2021

Registration Date

Not Registered

Published for Opposition

December 6, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 9, 2026 MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 9, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 9, 2026 ABN6
ABANDONMENT - NO USE STATEMENT FILED
Mar 9, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2025 EXRA
SOU EXTENSION 5 GRANTED
Dec 10, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 10, 2025 AITU
SOU EXTENSION 5 FILED
Jun 24, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Jun 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jan 7, 2025 EX4G
SOU EXTENSION 4 FILED
Jan 7, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 7, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 29, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jul 29, 2024 EX3G
SOU EXTENSION 3 FILED
Jul 29, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 29, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jan 3, 2024 EX2G
SOU EXTENSION 2 FILED
Jan 3, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 3, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 15, 2023 EXRA
SOU EXTENSION 1 GRANTED
Jul 13, 2023 EX1G
SOU EXTENSION 1 FILED
Jul 13, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 13, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 31, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 6, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 6, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 16, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 28, 2022 CNSA
EXAMINERS AMENDMENT -WRITTEN
Oct 28, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 27, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 2, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 2, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 2, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2021 NWOS
NEW APPLICATION ENTERED
Aug 5, 2021 NWAP